ABUS vs VIR
ABUS: A biopharmaceutical company advancing a clinical pipeline to treat chronic hepatitis B while monetizing its intellectual property through strategic licensing and litigation. VIR: Vir Biotechnology develops novel immunology-driven therapeutics targeting infectious diseases and cancer using proprietary T-cell engagement and masking technologies.
Side-by-side fundamentals
| Metric | ABUS | VIR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.33 | $9.35 | |
| Market cap as of 2026-07-23 | $862M | $1.6B | |
| P/E as of 2026-07-23 | 5.36 | n/a | |
| Net margin as of 2026-07-23 | +84.0% | -638.9% | ABUS higher |
| Gross margin as of 2026-07-23 | n/a | +100.0% | |
| Operating margin as of 2026-07-23 | +81.7% | -699.2% | ABUS higher |
| ROE as of 2026-07-23 | +129.3% | -49.3% | ABUS higher |
| ROA as of 2026-07-23 | +112.2% | -38.7% | ABUS higher |
| Debt / equity as of 2026-07-23 | 0.01 | 0.00 | VIR lower |
| Revenue growth (YoY) as of 2026-07-23 | +2889.9% | -7.6% | ABUS higher |
| Revenue CAGR (3y) SEC XBRL | -28.8% | -65.1% | ABUS higher |
| Beta as of 2026-07-23 | 0.60 | 1.60 | |
| 1-year return as of 2026-07-22 close | +37.5% | +70.7% | VIR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.